The treatment landscape for NSCLC continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies into new patient populations. Examples include the approvals of Alunbrig for ALK-positive metastatic NSCLC,Tafinlar plus Mekinist for BRAF-mutation-positive NSCLC, and Imfinzi for unresectable stage III NSCLC as well as the label expansion of Keytruda in combination with chemotherapy as a first-line regimen for metastatic nonsquamous patients. Our primary research provides insight into the current use of approved therapies for NSCLC in the United States and uncovers key factors that influence medical oncologists’ prescribing decisions in this highly dynamic indication.
Non-Small-Cell Lung Cancer | Access & Reimbursement | Detailed, Expanded Analysis (EU)
MARKET OUTLOOK Non-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, wh...
Non-Small-Cell Lung Cancer | Landscape & Forecast | Disease Landscape & Forecast
Market Outlook Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint inhibito...
Non-Small-Cell Lung Cancer | Geographic Focus: China | Non-Small-Cell Lung Cancer | China In-Depth | China
MARKET OUTLOOK Non-small cell lung cancer (NSCLC) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in China. NSCLC has one of...
Non-Small-Cell Lung Cancer | Current Treatment | Detailed, Expanded Analysis: Treatment Sequencing (US)
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.